revenu beat reflect strong uptak soliri gmg alongsid continu
growth pnh ahu guidanc consensu suspect
manag conserv guidanc ratchet
optimist rapid convers soliri ultomiri increas investor
confid prospect l-t revenu growth
alexion revenu ep beat consensu alexion guidanc
consensu full recap earn see previou note total revenu
y/i vs consensu driven double-digit volum
growth y/i partial off-set fx price headwind manag
note price headwind mostli caus cut soliri price turkey
follow formal reimburs agreement late revenu
favor impact addit tender order ex-u market
rel product sale growth deriv y/i
asia pacif row
soliri sale q/q y/i vs consensu driven
y/i volum growth favor impact approxim addit
tender order ex-u rel manag note revenu growth
driven primarili strength japan grow contribut gmg
number patient therapi grew q/q meanwhil underli volum
growth pnh ahu remain solid high singl digit throughout
strensiq y/i vs revenu consensu
continu underli volum growth y/i germani
alexion guid total revenu y/i midpoint
versu consensu soliris/ultomiri revenu vs consensu
approx non-gaap oper margin non-gaap ep
y/i midpoint vs consenu revenu guidanc assum
continu growth soliri gmg high singl digit growth pnh ahu continu
growth metabol franchis modest initi revenu expect
launch soliri nmosd alexion expect gmg patient constitut
largest popul patient soliri manag also note
sever expect headwind revenu growth includ price fx clinic trial
enrol chang row distribut alexion estim price
headwind attribut soliri attribut metabol
particular begin earli alexion proactiv offer rebat largest
vial strensiq net hedg alexion expect fx repres approxim
headwind driven euro fx chang turkey russia brazil headwind
enrol clinic trial includ competitor addit subq gmg
final alexion plan transit direct distributor model certain smaller
intern market approxim headwind revenu
adjust model consist guidanc soliris/ultomiri
estim increas total revenu estim
non-gaap ep estim similarli increas dcf-
pleas see page report import disclosur
alexion new manag team restor investor confid underli demand
trend soliri remain solid launch gmg set eclips launch pnh
ahu expect fear competit alexion key complement franchis
wain franchis transfer ultomiri follow januari launch strensiq
wit strong launch appear destin blockbust statu
asset plu minor contribut kanuma allow compani post
industry-lead financi view alexion premier orphan diseas compani
expect share appreci investor gain convict alexion abil convert
market ultomiri
file ultomiri approv ahu
phase ib/iia data waiha
 launch soliri nmosd
soliri sale transfer ultomiri
strensiq kanuma lal-d
achiev
transit franchis
ultomiri rapid assum
soliri ultomiri sale fall short
commerci regulatori setback
strensiq ultomiri
soliri experi meaning
soliri approv treatment paroxysm nocturn hemoglobinuria pnh
atyp hemolyt urem syndrom ahu next-gen ultomiri
approv pnh approv ahu anticip pnh autoimmun
disord mark red blood cell deplet believ affect estim
patient world-wide candid soliri given price
approxim estim ww peak annual sale
pnh ahu caus overactiv complement pathway often kidney
soliri shown improv multipl hallmark diseas believ
ahu market could compar size pnh market soliri also approv
gener myasthenia gavi gmg octob potenti new oppi beyond
soliri strensiq kanuma achiev commerci success
respect peak sale
sinc soliri launch pnh alexion built success commerci team
disease-specif expertis first year sinc soliri launch approxim
 ahu pnh patient put therapi
alexion aim add number patient onto therapi soliri ultomiri
approxim patient would treatment
compani track achiev goal expect addit approv ultomiri
soliri gener uptick patient add year ahead soliri launch gmg
best yet patient therapi prescrib approxim
prescrib soliri one gmg patient addit ultomiri may
expand pnh market patient compel initi therapi due ad
conveni six infusions/yr vs soliri final soliri expect gain approv
nmosd known popul treat center excel
fda approv treatment option soliri potenti captur sizabl proport
nmosd market address patient approxim
target gmg popul meaning reduct relaps rate expect creat
new standard treatment nmosd alexion expand sale footprint
anticip launch full data soliri phase trial nmosd expect
may late breaker submit
country-by-countri basi alexion expect convert least soliri pnh
patient ultomiri within two year launch -- ambit ultomiri
ahu approv like earli compani expect patient convert
ultomiri linear fashion believ bolu convers
begin launch ex-u alexion anticip materi revenu germani
launch expect mid-year launch japan follow though
announc call last week screen pnh patient phase
soliri biosimilar trial earliest amgen could enter market would approxim
three year -- alexion plan convert major market germani
japan ultomiri though speed ultomiri launch addit european countri
outsid germani impact alexion abil maintain market share pnh
territori germani soliri largest european market alexion aim
pnh patient convert ultomiri
follow ultomiri launch januari manag note initi stakehold
feedback posit manag highlight payor discuss
encourag especi given ultomiri ad conveni come alongsid
price discount hope rapid convers pnh patient soliri
ultomiri help allevi investor concern long term
sustain franchis
alexion develop conveni formul ultomiri also make
progress multipl neurolog program data phase trial once-weekli
subq expect alexion phase trial wilson
diseas on-going power superior standard care phase ib/iia trial
waiha pv/pf on-going pivot phase trial
waiha gmg plan addit pipelin updat provid
compani investor day march
last week alexion report top-lin data ultomiri phase treatment-na ahu
demonstr hematolog normal patient -- efficaci keep
soliri ahu morn call manag note compar ultomiri
result ahu soliri challeng given meaning
chang patient diagnosi manag sinc soliri trial ahu conduct
addit ahu patient ultomiri trial tend sicker patient older
dialysi symptom renal diseas base baselin ldh
level patient enrol ultomiri trial sever diseas alexion believ
ultomiri provid meaning conveni benefit ahu patient could
improv persist proport ahu patient soliri treat acut
short cours therapi furthermor price discount manag believ
addit ahu patient abl gain access therapi alexion plan submit
regulatori file follow eu japan
neurolog soliri demonstr abil improv complement-medi diseas
neuromuscular junction central nervou system thu alexion plan initi
phase trial ultomiri gmg nmosd well initi proof-of-concept studi
al primari progress multipl sclerosi ppm
alexion fcrn program studi first week iv formul
phase studi subq formul follow anti-fcrn
develop waiha pivot trial initi follow complet
on-going phase ib/iia pivot trial gmg plan would expand
treatment option patient earlier stage gmg complement alexion grow
mg portfolio note argenx fcrn develop mg well
administ iv data pivot phase expect plan announc
morn collabor halozym subq formul initi pk/pd data
anticip later
last week alexion announc collabor caelum biosceinc develop
treatment light chain amyloidosi alexion estim
approxim patient al amyloidosi standard
care al amyloidosi involv treatment plasma cell dyscrasia chemotherapi
elig high-dos chemotherapi follow sct prognosi depend
time diagnosi sever cardiac involv whether
concurr myeloma diseas often co-occur waldenstrom myeloma
lymphoma patient cardiac hepat failur median surviv month
patient limit organ involv median surviv year
standard care treatment phase ia/iib trial drug demonstr
improv mean nt-probnp level cardiac marker week refractori
patient enrol cardiac involv clinic dataset also includ
vivo imag bind amyloid protein human organ alexion
caelum process design phase ii trial set initi
like target enrol patient follow phase ii data read-out alexion
option acquir remain equiti compani
notabl previous develop antibodi al amyloidosi
discontinu phase develop last april base futil analysi -- phase
iib also meet primari secondari endpoint howev drug
differ protein target clinic efficaci valid vivo imag data
new manag done admir job stabil compani grow soliri
sale pnh ahu launch drug gmg indic think favor
financi outlook increas confid compani abil convert patient
ultomiri could posit share re-rat investor gain confid
growth durabl complement franchis maintain price target
soliri eculizumab human monoclon antibodi approv
treatment paroxysm nocturn hemoglobinuria pnh atyp
hemolyt urem syndrom ahu gener myasthenia gravi
gmg soliri becom one success ultra-orphan drug
sale y/i pivot trial soliri neuromyel
optica nmo releas posit phase data launch plan
next-gener soliri candid ultomiri seek advanc upon
soliriss profil offer greater conveni potenc phase studi
use dose paradigm demonstr non-inferior soliri
trend superior fda approv pnh grant end
decemb regulatori file ahu plan
 subq formul employ dose on-going
initi data anticip alexion also plan studi subq
co-administ halozym call could
extend dose interv given steadi new patient add
ultomiri abil protect franchis competit estim
sale alexion complement franchis includ pnh
ahu gmg alexion market two addit ultra-orphan
drug strensiq asfotas alfa hypophosphatasia sever bone
diseas approv europ japan gener
sale believ drug potenti alexion
acquir synageva bring kanuma enzym
replac therapi lal defici unfortun alexion face
challeng identifi lal-d patient sale like far
modest expect model sale alexion also
acquir wilson therapeut april gain access treatment
wilson diseas current phase develop addit
alexion acquir syntimmun alexion aim
move pivot develop warm autoimmun hemolyt anemia waiha
gmg view alexion premier orphan diseas compani expect
share appreci investor gain convict growth prospect
cowen compani
reportedcowen estimatesoliri percent percent percent cowen
full data phase nmosd
anticip launch nmosd
regulatori submiss soliri nmosd eu japan
phase data weekli subq
anticip launch pnh germani
file approv ahu
initi phase ultomiri iv gmg nmosd
initi poc studi ultomiri iv al ppm
data pk-base registr phase bridg studi weekli subq
data phase ib/iia trial waiha
initi phase trial waiha gmg
acquir in-licens addit earli stage candid
cowen compani
cowen compani
franchis y/i y/i y/i y/i sale y/i y/i y/i gross total product oper oper oper incom non- tax net incom y/i base compens incom includ stock includ stock comp cowen
cowen compani
franchis sale kanuma sale y/i gross total gener product oper incom tax net y/i includ stock comp cowen
cowen compani
oper activitiesnet incom net use oper activitiesnon-cash exit currency/hedg lossshare-bas compens conting gain loss forward contractsdef asset liabilitiesaccount expens payable/accru use oper invest activitieschang market acquisitionspurchas invest financ activitiesdebt issuanc excess tax benefit stock option mortagag note payableproce loan stock proce issuanc common stock financ fx chang cash equival begin cash equival end summari oper itemsbegin exclud non-recur itemsalexion statement flow cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
great major alexion valu deriv singl product soliri risk
expect soliri includ potenti slowdown pnh market unknown
size ahu market regulatori clinic develop risk indic
includ nmo mg alexion share could also wit meaning downsid
meet failur
